BCT vs. MBX, HBP, APS, ATE, RVX, AEZS, TH, ONC, MDNA, and SVA
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Microbix Biosystems (MBX), Helix BioPharma (HBP), Aptose Biosciences (APS), Antibe Therapeutics (ATE), Resverlogix (RVX), Aeterna Zentaris (AEZS), Theratechnologies (TH), Oncolytics Biotech (ONC), Medicenna Therapeutics (MDNA), and Sernova (SVA). These companies are all part of the "biotechnology" industry.
Microbix Biosystems (TSE:MBX) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations, risk and community ranking.
Microbix Biosystems has higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.
Microbix Biosystems has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.
Microbix Biosystems received 69 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 70.71% of users gave Microbix Biosystems an outperform vote.
Microbix Biosystems has a net margin of 16.57% compared to Microbix Biosystems' net margin of 0.00%. BriaCell Therapeutics' return on equity of 14.66% beat Microbix Biosystems' return on equity.
0.4% of Microbix Biosystems shares are held by institutional investors. Comparatively, 15.5% of BriaCell Therapeutics shares are held by institutional investors. 14.1% of Microbix Biosystems shares are held by company insiders. Comparatively, 17.2% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Microbix Biosystems had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Microbix Biosystems and 0 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.00 equaled Microbix Biosystems'average media sentiment score.
Summary
Microbix Biosystems beats BriaCell Therapeutics on 9 of the 13 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
